Clinical Trial Update: Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and pharmacokinetics of the fixed-dose combination VR 160/20 mg compared with co-administration of valsartan 160 mg and rosuvasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Hypertension

Drugs mentioned

• CRESTOR (Rosuvastatin)
• DIOVAN (valsartan)
• VR 160/20 (valsartan/rosuvastatin)

Snippet

Sponsor: LG Life Sciences | Conditions: Hypertension, Hyperlipidemia | Phase 1 | Status: COMPLETED